Proactive steps to optimize the management of polycythemia vera and myelofibrosis.
Authors: Mesa RA PMID: 31549966 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 26, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New treatment options for the management of acute graft-versus-host disease.
Authors: Chen YB PMID: 31549967 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 26, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer.
Authors: Rugo HS PMID: 31549968 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 26, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The newest treatments for uveal melanoma.
Authors: Luke JJ PMID: 31549969 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 26, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of JAK inhibitors in multiple myeloma.
Authors: Ghermezi M, Spektor TM, Berenson JR Abstract Multiple myeloma (MM) is the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. In recent years, new and more effective drugs have become available for the treatment of MM. Many newer drugs have been evaluated together and in combination with older agents. However, even in combination with other active MM agents, the responses are transient, and; thus, therapeutic approaches to help overcome resistance to these drugs are necessary. Recently, the Janus kinase (JAK) family of ...
Source: Clinical Advances in Hematology and Oncology - September 26, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Measurement of circulating tumor DNA to guide management of patients with lymphoma.
Authors: Sriram D, Lakhotia R, Fenske TS Abstract In recent years, advances have been made in methods to assess response to therapy in lymphoma. Ideally, response assessment tools should be highly sensitive and specific for identifying a disease, should carry a minimal risk of harm to the patient, and should provide reproducible results. Traditional surveillance methods have included clinical assessment and, in many cases, routine surveillance imaging. Minimal residual disease (MRD) refers to the detection of disease level below that of these traditional surveillance methods. Either circulating tumor cells or their...
Source: Clinical Advances in Hematology and Oncology - September 26, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Stereotactic body radiation therapy and immunotherapy.
This article reviews the association between the immune system and cancer, as well as the additional systemic benefit that SBRT can have in patients with advanced-stage malignancies being treated with immunotherapy. PMID: 31549973 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 26, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting.
Authors: PMID: 31545304 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 25, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting: A hematologist's perspective.
Authors: Haverkos B PMID: 31545305 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 25, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting: A dermatologist's perspective.
Authors: Geskin LJ PMID: 31545306 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 25, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
Authors: PMID: 31545307 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 25, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting: commentary.
Authors: O'Brien SM PMID: 31545308 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 25, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting.
Authors: PMID: 31545309 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 25, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting: commentary.
Authors: Mesa RA PMID: 31545310 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 25, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

PSMA PET/CT for staging and treatment of prostate cancer.
Authors: Hofman M PMID: 31449501 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Update on transfusion-related acute lung injury.
Authors: Toy P PMID: 31449502 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Authors: George DJ PMID: 31449503 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Insights into the management of older patients with multiple myeloma.
Authors: Anderson KC PMID: 31449504 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Improving the disclosure of conflicts of interest in medicine.
Authors: Arnold D PMID: 31449505 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Risk factors for and clinical management of venous thromboembolism during pregnancy.
Authors: Rybstein MD, DeSancho MT Abstract Venous thromboembolism (VTE), which comprises deep vein thrombosis and pulmonary embolism, is one of the leading causes of non-obstetric maternal death in the United States. Physiologic and anatomic changes associated with pregnancy set the stage for a hypercoagulable state. In addition, other risk factors-including those associated with certain fetal characteristics such as low birth weight or stillbirth-have been correlated with an increased risk for VTE. Women with a personal or strong family history of VTE, as well as documented thrombophilia, represent a unique group ...
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of advanced phase myeloproliferative neoplasms.
This article reviews management considerations for the advanced-phase MPNs (MPN-AP and MPN-BP), with a special focus on MPN-AP, and highlights novel experimental therapies. PMID: 31449507 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in breast cancer from the 2019 American Society of Clinical Oncology annual meeting.
Authors: PMID: 31449508 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A rational approach to the development of drug combinations in thoracic oncology.
Authors: Camidge DR PMID: 31449509 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

When to use triplet chemotherapy as first-line treatment in metastatic colorectal cancer.
Authors: Cremolini C PMID: 31449510 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
Authors: Seymour J PMID: 31449511 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of rare epithelial ovarian cancers.
Authors: Gershenson DM PMID: 31449512 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Next-generation sequencing for the general cancer patient.
Authors: Avila M, Meric-Bernstam F Abstract Next-generation sequencing is a novel method of DNA sequencing that has become a cornerstone of precision oncology. This sequencing method detects differences in specific DNA sequences between a sample and a reference genome or matched normal DNA. In addition to single-nucleotide variants, other insertions, deletions, copy number changes, and fusions may be drivers of cancer growth, and thus represent therapeutic opportunities. As a result, genomic characterization has been increasingly used to guide treatment decisions, especially in patients with advanced disease. This ...
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Imaging of prostate cancer with positron emission tomography.
Authors: Zimmerman ME, Meyer AR, Rowe SP, Gorin MA Abstract Prostate cancer is most commonly imaged through a combination of magnetic resonance imaging, x-ray computed tomography, and 99mTc-methylene diphosphonate bone scan. These conventional imaging modalities, however, suffer from limited sensitivity and specificity for the detection of disease. This can lead to disease understaging and the improper selection of treatment. To address this problem, a variety of novel radiotracers for positron emission tomography (PET) imaging have been developed. This includes agents that accumulate on the basis of alterations in...
Source: Clinical Advances in Hematology and Oncology - August 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Midostaurin for patients with acute myeloid leukemia and FLT3 mutations.
Authors: Levis MJ PMID: 31437132 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 24, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Venous thromboembolism in children.
Authors: Goldenberg NA PMID: 31437133 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 24, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Optimizing drug dosing for the treatment of chronic lymphocytic leukemia.
Authors: Jain N PMID: 31437134 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 24, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The dawn of immunotherapy for breast cancer.
Authors: Emens LA PMID: 31437135 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 24, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in kidney cancer.
Authors: PMID: 31437136 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 24, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How I treat cold agglutinin hemolytic anemia.
Authors: Gertz MA PMID: 31437137 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 24, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Diagnosis and treatment of hemophilia.
Authors: Kizilocak H, Young G Abstract Hemophilia A and B are inherited bleeding disorders characterized by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and muscle bleeds are the major clinical manifestations. Replacement therapy with clotting factors, either at the time of bleeding or as part of a prophylactic regimen, is adapted to individual patient needs. The major complication of therapy is the development of neutralizing antibodies. In response, researchers have developed novel agents to both reduce the treatment burden and prevent bleeding regardless of ...
Source: Clinical Advances in Hematology and Oncology - August 24, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Surveillance scanning in lymphoma.
Authors: Rutherford SC Abstract Although the role of imaging in the management of most lymphomas is well established at baseline, during treatment, and following treatment, surveillance imaging after complete response remains controversial despite the numerous studies that have investigated follow-up computed tomography, positron emission tomography, and magnetic resonance imaging over the past 20 years. Although robust data do not support an impact of this strategy on survival in Hodgkin lymphoma, diffuse large B-cell lymphoma, or follicular lymphoma, many patients continue to undergo serial imaging studies. The r...
Source: Clinical Advances in Hematology and Oncology - August 24, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunotherapy in colorectal cancer with mismatch repair deficiency.
Authors: Overman MJ PMID: 31188802 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia.
Authors: Kantarjian HM PMID: 31188803 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How we treat locally advanced HER2-positive breast cancer.
Authors: Exman P, Pernas S, Tolaney SM PMID: 31188804 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Developing a career in a hybrid academic/community practice.
Authors: Braunstein M PMID: 31188805 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New approaches to immunotherapy for metastatic castration-resistant prostate cancer.
Authors: Subudhi SK PMID: 31188806 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Insights into the increasing costs of cancer drugs.
Authors: Bach PB PMID: 31188807 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Optimal duration of adjuvant therapy for stage III colon cancer.
Authors: Kadakia KC, Worrilow WM, Coley H, Salem ME Abstract Colon cancer remains a major cause of mortality worldwide. Following adequate surgical resection of lymph node-positive colon cancer, the standard of care since 2004 has been to administer an oxaliplatin-containing regimen (eg, FOLFOX or CAPOX) for 6 months. These regimens have consistently improved oncologic outcomes compared with non-oxaliplatin therapies in multiple adjuvant randomized controlled trials. However, oxaliplatin-induced cumulative dose-dependent neurotoxicity is a major cause of morbidity that can persist years after treatment. The IDEA co...
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
Authors: Masarova L, Verstovsek S Abstract Myelofibrosis (MF) is the most aggressive of the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). In some patients with essential thrombocytopenia or polycythemia vera, which are relatively benign MPNs, MF develops as a natural evolution of their disease, resulting in post-essential thrombocythemia myelofibrosis (PET-MF) or post-polycythemia vera myelofibrosis (PPV-MF). Presenting with the same clinical features, including debilitating symptoms and signs of bone marrow failure, PET/PPV-MF has traditionally been considered akin to primary myelof...
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Treatment advances in blastic plasmacytoid dendritic cell neoplasm.
Authors: Pemmaraju N PMID: 31188810 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Authors: Wierda WG PMID: 31188811 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Enhanced recovery after surgery for ovarian cancer.
Authors: Dowdy SC PMID: 31188812 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Toxicities of checkpoint inhibitors: causes and management.
Authors: Postow MA PMID: 31188813 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Authors: Bond DA, Alinari L, Maddocks K Abstract Mantle cell lymphoma (MCL) is a heterogeneous and uncommon non-Hodgkin lymphoma that affects predominantly older patients and often is associated with an aggressive clinical course. MCL relies upon B-cell receptor signaling through Bruton tyrosine kinase (BTK); therefore, the development of the BTK inhibitors ibrutinib and acalabrutinib represents a therapeutic breakthrough. In this review, we provide a summary of the efficacy and safety data from the landmark trials of single-agent ibrutinib and acalabrutinib that led to US Food and Drug Administration approval of t...
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Antiplatelet agents for preventing vaso-occlusive events in people with sickle cell disease: a systematic review.
CONCLUSIONS: The current evidence does not support or reject the use of any antiplatelet agent for preventing VOEs in people with SCD. This conclusion was based on small RCTs that carried a high risk for bias. No conclusive evidence exists regarding relevant clinical outcomes because the evidence is limited and of very low quality. PMID: 31188815 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research